✦ LIBER ✦

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Scribed by Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner; Michael J. Keating

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 34 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25434

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab by continuous intravenous in

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

✍ Stefan Faderl; Alessandra Ferrajoli; William Wierda; Susan O'Brien; Susan Lerner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO